A Phase 3 interventional study of Atomoxetine and Placebo in Parkinson's Disease (PD), Freezing of Gait and Freezing of Gait Symptoms in Parkinson Disease, sponsored by Radboud University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Radboud University Medical Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Parkinson Disease by Radboud University Medical Center — 6 open to participants now, 12 under way, 1 of them phase 3. Parkinson Disease · Radboud University Medical Center.
Among the 34 studies in Parkinson Disease by Radboud University Medical Center, this one is the 16th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 3, reaches primary completion later than 9 of the 11 other live ones, and was the 34th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →6 of the 34 studies in Parkinson Disease by Radboud University Medical Center are open now, in 2 countries. Recruiting first, the newest first:
Radboud University Medical Center · Sites in United States, Netherlands
Ages 50+
Radboud University Medical Center · Sites in Netherlands
Ages 50+
Radboud University Medical Center · Sites in Netherlands
Ages 18+ · Healthy volunteers
Radboud University Medical Center · Sites in Netherlands
Ages 18+
Radboud University Medical Center
Ages 30–75
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 60 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 188 across the 22 interventional studies, 133 across the 12 observational. Of the 19 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
Radboud University Medical Center is the lead sponsor of 986 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Parkinson Disease by Radboud University Medical Center that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07316296Phase 3Radboud University Medical CenterPharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach | 2027-07-01 |
| NCT06669455Radboud University Medical CenterAn Integrated and Personalized Lifestyle Approach for People With Parkinson's Disease | 2027-03 |
| NCT06573866Radboud University Medical CenterEnhancement of Quality of Work And Life | 2027-03-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 34 studies in Parkinson Disease by Radboud University Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if the medication atomoxetine can reduce freezing of gait in people with Parkinson's disease. The main questions it aims to answer is:
Does atomoxetine reduce the frequency or severity of freezing of gait? What role does noradrenaline play in freezing of gait?
Researchers will compare atomoxetine to a placebo to see if atomoxetine can improve freezing of gait in people with Parkinson's disease.
Participants will:
Visit the study site for measurements Take atomoxetine or placebo Perform walking assessments and undergo MRI Complete questionnaires about anxiety, stress, and quality of life
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Atomoxetine · Drug: Placebo
Drug: Atomoxetine · Drug: Placebo
Single dose, 40mg atomoxetine, capsule
Single dose, placebo (microcrystalline cellulose), capsule
The percentage of time frozen in the dopaminergic OFF-state
Time frame: Baseline, visit 2 (one week after baseline) and visit 3 (one week after visit 2).
The percentage of time frozen in the dopaminergic ON-state
Time frame: Baseline, visit 2 (one week after baseline) and visit 3 (one week after visit 2).
The brain network integration-segregation coefficient
Time frame: Visit 2 (one week after baseline) and visit 3 (one week after visit 2).
Started Jan 2026 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.
Of 68 phase 3 interventional studies under Parkinson Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 18 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atomoxetine
Radboud University Medical Center →